Sort   by:  
 Page size 
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
GenomicsPARPi resistance screens in BRCA2-deficient cells
PARPi resistance screening in KB2P-3.4 2D cell lines
PRJEB74933 | ENA
GenomicsRole of ALDH1A1 in PARPi resistance in ovarian cancer
Role of ALDH1A1 in PARPi resistance in ovarian cancer
PRJNA938376 | ENA
GenomicsPARPi resistance CRISPR screen in WEHI-CS62
Genome-wide PARPi (Rucaparib) resistance CRISPR screen in BRCA1 methylated ovarian cancer cell line WEHI-CS62
PRJEB114638 | ENA
GenomicsMYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.
PRJNA1334427 | ENA
TranscriptomicsRole of ALDH1A1 in PARPi resistance in ovarian cancer
Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum. However, the acquired resistance ...
ORGANISM(S): Homo sapiens 
2023-07-19 | GSE226018 | GEO
TranscriptomicsMYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the first direct MYC inhibitor to pass a Phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNB...
ORGANISM(S): Homo sapiens 
2025-09-26 | GSE309250 | GEO
UnknownMechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma.
Not available
S-EPMC12392133 | biostudies-literature
GenomicsRNA-Seq of PARPi-resistant ovarian cancer cells
RNA-Seq of PARPi-resistant ovarian cancer cells
PRJNA988124 | ENA
Sort   by:  
 Page size